184 - Do anti-psychotic medications improve oral sedation outcomes in ASD patients?

Purpose:  To determine if there is a significant difference in the outcome of oral conscious sedation of ASD patients taking an anti-psychotic versus those not on medication. 

Methods:  This retrospective chart review evaluated the in-office oral conscious sedation records of autistic patients 5-9 years old. Inclusion criteria was the first sedation visit using demerol and hydroxyzine, age, and medical history. All sedations were completed by a CMC pediatric dental resident. Data collected included medication prescribed to include none, aripiprazole or risperidone, and success or failure of the OCS visit based on patients frankl score reported by the resident in the chart note. Data was stratified based on anti-psychotic medication usage or not and outcome, failure or success, of the OCS visit.

Results: 49 patients met the inclusion criteria. Data was collected between Feb 2021 to Oct 2023. A fishers exact test was run with a two tailed P value = .033 which shows significance of the observed data set. ASD patients not on an FDA approved anti-psychotic medication showed a success rate of 36%. ASD patients with a prescribed FDA approved anti-psychotic medication showed an 86% success rate.

Conclusions: ASD patients taking FDA approved anti-psychotic medications showed a higher oral conscious sedation success rate than ASD patients not on an FDA prescribed medications. Further studies should be conducted on a larger population size to determine statistical significance.